Holen Sie sich die Stockscreener-App
0.99
2.94%
-0.03
Handel nachbörslich:
.99
Schlusskurs vom Vortag:
$1.02
Offen:
$1.02
24-Stunden-Volumen:
2.17M
Relative Volume:
0.88
Marktkapitalisierung:
$386.46M
Einnahmen:
$86.26M
Nettoeinkommen (Verlust:
$-50.08M
KGV:
4.9774
EPS:
0.1989
Netto-Cashflow:
$-94.48M
1W Leistung:
+5.88%
1M Leistung:
+11.83%
6M Leistung:
-16.81%
1J Leistung:
-7.48%
1-Tages-Spanne:
$0.985
$1.026
1-Wochen-Bereich:
$0.926
$1.03
52-Wochen-Spanne:
$0.8701
$1.72
Standard Biotools Inc Stock (LAB) Company Profile
Firmenname
Standard Biotools Inc
Sektor
Branche
Telefon
(650) 266-6000
Adresse
50 MILK STREET, BOSTON
Compare LAB vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LAB
Standard Biotools Inc
|
0.99 | 398.18M | 86.26M | -50.08M | -94.48M | 0.1989 |
ABT
Abbott Laboratories
|
82.56 | 146.87B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
282.58 | 109.33B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
74.54 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
53.37 | 80.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
77.17 | 46.04B | 6.30B | 1.07B | 1.09B | 1.8406 |
Standard Biotools Inc Stock (LAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-13 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-27 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2024-04-16 | Eingeleitet | TD Cowen | Buy |
| 2024-04-04 | Eingeleitet | Jefferies | Buy |
| 2023-07-12 | Eingeleitet | KeyBanc Capital Markets | Overweight |
Standard Biotools Inc Aktie (LAB) Neueste Nachrichten
Standard BioTools Inc. (LAB) Stock Analysis: A 55% Potential Upside Beckons Investors - DirectorsTalk Interviews
LAB Stock Price, Quote & Chart | STANDARD BIOTOOLS INC (NASDAQ:LAB) - ChartMill
Standard Biotools Faces Nasdaq Delisting Risk After Prolonged Sub-$1 Share Price - TipRanks
Number of shareholders of Standard BioTools Inc. – NASDAQ:LAB - TradingView
Standard BioTools (LAB) Premium P/S Multiple Tests Narratives After Another Quarterly Loss - Sahm
Standard BioTools (NASDAQ: LAB) posts Q1 2026 profit on SomaScan sale windfall - Stock Titan
MSN Money - MSN
Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry - MSN
Standard BioTools (LAB) reports Q1 loss, tops revenue estimates - MSN
Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Standard BioTools: Q1 Earnings Snapshot - marketscreener.com
Standard BioTools Highlights Improved Q1 2026 Results, Outlook - TipRanks
Standard BioTools 1Q Loss $14.6M >LAB - Moomoo
Standard BioTools 1Q Rev $21.1M >LAB - Moomoo
Standard BioTools ends quarter with $524M as loss shrinks 54% - Stock Titan
Standard BioTools (LAB) Q1 2026 results show big cash boost and EBITDA gains - Stock Titan
Standard BioTools Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Standard BioTools Reports First Quarter 2026 Financial Results - ChartMill
Standard BioTools posts Q1 2026 revenue growth and narrows losses, aiming for profitability this year - Pluang
Standard BioTools to Announce First Quarter 2026 Financial Results on May 5, 2026 - Investing News Network
Standard BioTools Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
LAB Standard BioTools beats Q4 2025 EPS projections by wide margin, shares rise nearly 5 percent today.Decline Phase - newser.com
Standard BioTools Inc. (NASDAQ:LAB) Sees Significant Drop in Short Interest - MarketBeat
Standard BioTools (LAB) Projected to Post Earnings on Tuesday - MarketBeat
[ARS] STANDARD BIOTOOLS INC. SEC Filing - Stock Titan
Standard BioTools (NASDAQ: LAB) details 2026 votes and Illumina deal cash boost - Stock Titan
Standard BioTools (LAB) Price Target Decreased by 12.68% to 1.58 - MSN
Standard BioTools Receives Nasdaq Minimum Bid Price Deficiency Notice - The Globe and Mail
Standard BioTools Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Finanzdaten der Standard Biotools Inc-Aktie (LAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):